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1. Introduction
The initial clinical description of Down syndrome (DS) was
made by Down in 1866 [1] and identified as trisomy of
chromosome 21 by Lejeune et al. in 1959 [2]. DS, or trisomy 21, is one of the most common causes of intellectual
disability (ID), and recent national prevalence estimates suggest that 14.47 per 10,000 live births are infants with DS,
leading to an average of 6037 annual DS births [3]. This
represents an increase from previous prevalence rates. Characteristic physical features, deficits in the immune and endocrine systems, and delayed cognitive development [4] can
be present in children with DS.
Improvements in medical care for children and adults
with DS have led to significant extensions in lifespan and
enhanced quality of life. As a consequence, up to 35 years
of age, mortality rates are comparable in adults with DS to
individuals with ID from other causes. However, after age 35,
mortality rates double every 6.4 years in DS, as compared
to 9.6 years for people without DS [5], and the currently estimated life expectancy of a 1-year-old child with
DS is between 43 and 55 years (depending on the level
of disability). Although longevity in adults with DS has
been increasing progressively, these increases have been substantially lower for some minority groups [6, 7]. Further, as
described by L. Thorpe et al., adults with DS are still disadvantaged compared to adults with other types of ID in
terms of mortality rate, with multiple comorbidities being

of significant concern (e.g., depression, seizures). Significant
contributors to quality of life in aging individuals with DS
also include gait disturbances (B. A. Smith et al.) and ophthalmic disorders (e.g., S. J. Krinsky-MC. Hale et al.), both of
which increase with age.

2. Dementia and Aging in DS
A key concern to aging adults with DS is the increasing risk
for developing Alzheimer’s disease (AD). The profile and
sequence of cognitive impairments in adults with DS are
similar to those seen with AD in the general population
[8–13]. Memory processes are aﬀected early in the course
of DS dementia [14]. Severe cognitive deterioration, such as
acquired apraxia and agnosia, has been reported in 28% of
individuals with DS at age 30 years, with a higher prevalence
of these impairments in the subsequent years [8, 9]. The
earliest manifestations of dementia in DS may involve
changes in personality and behavior [15–17]. Pragnosia or
socially deficient communication may be an early sign of
frontal lobe dysfunction in DS and can represent a striking
change from previous well-developed social capacities [18].
Individuals with DS typically show less of a decline in
language compared to performance skills associated with
aging throughout adulthood as compared to individuals with
ID but not DS [19]. The diagnosis of dementia in DS can
be challenging against the background of pre-existing intellectual impairment. Standardized criteria for the diagnosis
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of dementia in DS include both informant-based and direct
measures [16, 20–22]. The severity of preexisting cognitive
impairment may also be a predictor of the rate of cognitive
deterioration in DS [23].
Potentially modifiable risk factors are now being identified that can lead to enhanced susceptibility to dementia
in people with DS [24]. For example, women with DS may
develop dementia 10–20 years earlier than women in the general population [9, 25, 26]. One possible mechanism underlying increasing dementia risk for women with DS is suggested by J. H. Lee et al. The study describes a genetic polymorphism in the hydroxysteroid-17β-dehydrogenase gene
that is responsible for converting estrone to estradiol. Polymorphisms of this gene may lead to changes in activity of
hydroxysteroid-17β-dehydrogenase and modify circulating
levels of neuroprotective estrogen. In a cohort of women with
DS followed longitudinally, the onset of dementia was linked
to three of five single nucleotide polymorphisms (SNPs) in
this gene, and women with high-risk SNPs were 2-3 times
more likely to develop AD.

3. Neurobiology of Aging in DS
Middle-aged individuals with DS develop AD pathology
[25, 27–29], no doubt contributing to their high risk of
developing dementia [9, 30]. Still, not every individual
with DS will develop dementia. Although clinical signs of
dementia are more commonly observed when individuals
are over 50 years of age [9, 31–33], by 40 years of age,
virtually all individuals with DS have neuropathological
changes that are consistent with AD, including senile plaques
and neurofibrillary tangles (NFT) [13, 27, 28]. Senile plaques
contain the beta-amyloid peptide (Aβ) toxic to neurons and
thought to be a causative event in the pathogenesis of AD
[34, 35].
DS involves the overexpression of the amyloid precursor protein (APP) on chromosome 21. APP is cleaved
sequentially by beta- and gamma-secretases to release Aβ,
which forms toxic conformations and aggregates (e.g.,
senile plaques) in the AD and DS brain [34]. Indeed, the
development of AD neuropathology in most individuals with
DS after the age of 40 years is considered to be key evidence
in support of the amyloid cascade hypothesis as a cause for
sporadic AD. Beta-secretase has been characterized as the
enzyme beta-amyloid cleaving enzyme (BACE), of which a
homologous version, BACE2, is present on chromosome 21
[36]. However, despite increases in BACE2 mRNA in DS
brain, protein levels appear similar in DS compared to nonDS brain. Further, BACE2 activity appears to decrease the
production of Aβ from APP in contrast to the activity of
BACE1. R. L. Webb and M. P. Murphy also describe evidence
that BACE activity overall is not increased in the aged DS
brain, leading to the conclusion that APP overexpression
may be the prime cause of Aβ overproduction. It is also
fascinating to consider that despite earlier ages of onset of
Aβ deposition in the brain (∼30 years), people with DS are
able to compensate for progressive AD neuropathology and
many people with DS do not show signs of cognitive decline
until their 50s or even later [24]. Similarly, there are people
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without DS who by imaging studies or autopsy examinations
show Aβ deposition in the brain but are clinically normal,
suggesting that similar compensatory processes may also
occur [37–39].
A novel hypothesis is also provided by A. Reed-Cossairt
et al. regarding a role for reduced clearance of Aβ as a consequence of slower cerebrospinal fluid (CSF) turnover. In
addition, vascular dysfunction, specifically in the jugular
reflux, may be a significant contributor to slowed CSF turnover and the development of dementia in adults with DS. An
additional consequence of reduced vascular function may be
the development of white matter neuropathology that is typically seen in AD. Many gaps in our knowledge regarding
this potential feature of aging in DS that could be modified
with appropriate interventions are also discussed by ReedCossairt.
Additional neurobiological events that may impact the
risk of dementia may also compromise cognition in DS. As
summarized by J. P. Lockrow et al., a loss of neurons in
the locus coeruleus and basal forebrain (BFCNs) can lead to
reductions in two neurotransmitters that play a critical role
in learning and memory, norepinephrine, and acetylcholine. Further, these authors provide additional data suggesting that reduced norepinephrine may also lead to increased
neuroinflammation and degeneration in the hippocampus
(another area critical for memory). Reduced neurotransmitter levels in DS may also lead to a loss of trophic support
for neurons in the DS brain with age. Based upon research
in mouse models of DS (described in detail by G. N. Vacano
et al.), a loss of brain derived neurotrophic factor (BDNF)
occurs in response to norepinephrine losses and leads to cognitive deficits. A decrease in BDNF, in turn, has been linked
to enhanced vulnerability of neurons to oxidative stress, suggesting a cycle of increasing insults that may eventually lead
to neurodegeneration or death.
Oxidative damage has been extensively studied in people
with DS, because a significant number (>10) of genes
encoding proteins relevant to oxidative damage [40–42]
and ROS production located on chromosome 21 [43].
Many of these are overexpressed in DS. SOD1 has been
perhaps the most studied protein with regard to ROS metabolism in DS. Increased levels of this endogenous antioxidant
without parallel increases in catalase can lead to higher levels
of hydrogen peroxide. As reviewed by M. Perluigi et al., oxidative damage may be a significant contributor to neurodegeneration associated with the AD neuropathology seen
in DS with advancing age. Specifically, in the aging DS
brain, the presence of age-associated Aβ can in turn cause
oxidative damage, but there is also evidence that compensatory mechanisms may support normal neuronal function
until some threshold is crossed. Further, changes in mitochondrial functioning may produce damaging free radicals
that contribute to oxidative stress, given that we see higher
levels of mitochondrial DNA mutations in DS (P. E. Coskun
and J. Busciglio), although the combination of mitochondrial dysfunction and oxidative stress may lead to adaptive
responses in DS, perhaps prior to the development of
AD.
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Aβ and oxidative damage may contribute to brain
inflammation, either independently or in concert. Neuroinflammation, however, has not been studied as extensively as
these two other markers of neuropathology and represents
an area of focus that may be highly relevant to aging in DS
(D. M. Wilcock) [44, 45]. Given that genes involved with
neuroinflammation are located on chromosome 21, the neuroinflammatory milieu in DS may be diﬀerent from AD in
the general population. For example, S100β is present in
triplicate in DS, is expressed by astrocytes, and is released
in response to inflammatory cytokines. As shown in Table
1 of the review by D. M. Wilcock, this is one of multiple
genes that could lead to enhanced neuroinflammation in
DS, although these genes may also prime the brain towards
an M1 inflammatory response. Inflammatory responses may
lead to enhanced vulnerability of DS neurons in the presence
of Aβ—tangles and oxidative damage—and could be a significant target for intervention. Neuroinflammation has not
been fully explored as a function of age in DS and is an active
area of research in AD in the general population.
G. Tansley et al. provide novel evidence that circulating
levels of 24S-OH-cholesterol, thought to reflect brain levels
of cholesterol, are unchanged in aging individuals with DS
compared to those without DS. Further, the overall lipid
metabolism profile of plasma observed in DS is similar to
those without DS. The exception may be brassicasterol levels,
which are reduced for older DS individuals compared to
those without DS. While this is a very intriguing finding and
may reflect AD-associated neuropathology, this is the first
report of the eﬀect and further confirmation is required.

4. Pharmacological and Nonpharmacological
Intervention Strategies
There are only 5 FDA-approved drugs for the treatment
of AD in the general population, and these have met with
moderate or little success for the treatment of AD in DS [46–
51]. This suggests that other disease-modifying approaches
are going to be critically important for future therapeutics.
Prevention, however, may be the most promising approach to
healthy aging in DS and may include both pharmacological
and nonpharmacological interventions.
Critically important to the development of novel therapeutics or prevention strategies is the use of mouse models
for DS where promising strategies can be first tested. There
are several mouse models for DS that capture developmental
and aging-associated phenotypes (G. N. Vacano et al.).
Although DS is a complex genetic disorder, careful dissection
of the role of individual or groups of genes to the DS phenotype provides an exciting approach for the development
of new interventions. In combination with existing mouse
models for AD, promising new pharmacological or nonpharmacological treatments may be identified. However, it is also
critical to note that translation of outcomes from mouse
studies to human clinical trials is not necessarily direct, but
the mouse studies provide important proof of principle outcomes that can be pursued.
As one example of using this approach, J. P. Lockrow et al.
review studies suggesting that the norepinephrine precursor
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L-threo-DOPS (Droxidopa) can improve learning and memory in DS mice and may be a possible target for DS clinical
trials addressing improvement of age- and AD-associated
cognitive dysfunction. As a parallel component to enhancing
norepinephrine function, neuroinflammation appears to be
intimately linked to the levels of this neurotransmitter and
increased in DS aging mice.
Another pharmacological approach to preventing AD
in people with DS may be to modify the production of
Aβ due to overexpression of APP (R. L. Webb and M. P.
Murphy). Clinical trials are currently addressing the reduction of BACE activity in sporadic cases of AD (http://www
.clinicaltrials.gov/), but gamma-secretase inhibitors may not
be a viable option given adverse side eﬀects. An intriguing
report in a mouse model of DS showed that reducing BACE
activity in young animals reduced learning and memory
deficits, suggesting that APP overexpression and production
of Aβ may not only be involved with AD development with
age but also contribute to intellectual disability in younger
individuals [52].
Reducing oxidative damage (which is a lifelong issue
for DS) may require a multitargeted approach that is preventative in nature, given that supplementing demented
adults with DS with antioxidants (or individuals with AD in
the absence of DS) has shown little or no benefit to clinical outcomes [53]. Indeed, compensatory mechanisms at
younger ages in DS may be enhanced by antioxidant supplementation (M. Perluigi and D. A. Butterfield). Focusing on
mitochondrial dysfunction is also a promising approach, as
these organelles are the primary producers of reactive oxygen
species (P. E. Coskun and J. Busciglio). In addition, isolated
mitochondria have a higher rate of DNA mutations, suggesting a progressive exacerbation in mitochondrial function in
DS. Given this evidence for mitochondrial dysfunction in
DS, there are several possible interventions that may reduce
age-associated declines (e.g., dietary changes and/or supplementation with mitochondrial cofactors). A combinatorial
approach may be particularly valuable for adults with DS
who may benefit from a supplement including both antioxidants (e.g. vitamins E and C) and mitochondrial cofactors (e.g., lipoic acid, acetylcarnitine). However, it may
be critical to use these approaches as a preventative measure
rather than as a treatment protocol for AD in DS [53]. Given
the interaction between Aβ, oxidative damage and neuroinflammation, and the relative paucity of data regarding
inflammation in the aging DS brain, unexplored potential
new targets for intervention may exist (D. M. Wilcock).
Several key issues highlighted in this special issue topics
suggest that lifestyle modification and regular health monitoring may also lead to successful aging in people with
DS. For example, although older adults show decreased
stability and eﬃciency in gait during walking, evidence for
adaptation suggests potential for improvements with appropriate interventions (B. A. Smith et al.). Changes in gait
should be taken into consideration, as they may lead to less
physical activity and/or functional decline.
A substantial number of people with DS develop ophthalmic disorders, aﬀecting up to 50% of adults between
50 and 59 years of age (S. J. Krinsky-MC. Hale et al.).
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The development of age-associated visual deficits occurs at
younger ages in DS than that in the general population.
The presence of ophthalmic disorders is higher in DS individuals with more severe intellectual disability, leading to
additional challenges and significant functional consequences. Interestingly, in S. J. Krinsky-MC. Hale’s report of longitudinally followed individuals with DS, cataracts were the
most frequent problem in older adults but were not associated with the level of ID. However, the presence of cataracts does compromise functioning and readily available
treatments can improve quality of life for aﬀected individuals
with DS.
Diet may be a very important area to consider for healthy
aging in DS. For example, the reduced levels of brassicasterol
reported by G. Tansley et al. may be modifiable by diet.
Whether this would mechanistically reduce the development
of AD or impact on longitudinal changes in cognition has yet
to be determined. Additionally, managing estrogen levels in
aging women with DS may help to reduce their risk for developing AD dementia, but an individualized approach including genetic risk as determined by the presence of SNPs on the
HSD17B1 gene may need to be incorporated (J. H. Lee et al.).

5. Summary
This special issue of the Current Gerontology and Geriatrics
Research journal was intended to cover selected issues defining the concerns faced by adults with Down syndrome as
they grow older. As can be seen from this selection of papers,
substantial gaps in our knowledge of the aging process in
people with DS continue to persist and are critically important to address. Further, approaches for maintaining healthy
aging in individuals with DS may also inform strategies for
enhancing quality of life for other adults with ID or indeed
in the general population. Ongoing longitudinal studies that
monitor changes in health status, cognition, function, the
development of dementia, and mortality will all be critically
important for informing the development of policies and
interventions to promote healthy aging in DS. A key challenge to aging adults with DS is the increasing risk for developing dementia; yet our social and medical infrastructure is
not as well prepared for providing care to adults with DS as
they age relative to the outstanding support available to children with DS and their families. The use of FDA-approved
treatments for AD in the general population has met with
limited success in people with DS [46]. Therefore, it is critically important to explore novel interventions and potential
prophylactic approaches that may provide individuals with
DS the best possible opportunity to age gracefully. Such
interventions along with further study of aging, dementia,
and Alzheimer disease in DS are likely to be of fundamental
importance in understanding AD in the general population.
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